Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|August 19, 2002
New HIV guidelines call for later start in treatment
HIV retroviral therapy recommendations
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
3
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5